Option chain shows key data for Senti Biosciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Senti Biosciences.

Senti Biosciences (NASDAQ:SNTI) Stock, Option Chain

Senti Biosciences

Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.

AT&T

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

BASE

HNST

MRVL

SNTI

TRMB

AT&amp;T To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday

Fat Bear Week Returns

Equities

General

$BTC

INTC

SHIM

SMCI

TSLA

U.S. stock futures were in negative territory during Tuesday’s premarket hours as the dollar slipped to 106.3 level.

US Stock Futures Dip As Dollar Slides And Treasuries Rise After S&amp;P Hits 54th All-Time High This Year: Analyst Sees &#39;Further Upside&#39; Of Around 10% In 2025 From Current Levels

Wall street.Stockmarket.Stock,Traders,Pointing,Highest,Stock,Market,On,Dynamic,Valued,Analysis

Earnings

Eurozone

Commodities

MOND

NVCR

RVMD

UPST

Dow Dips 150 Points; ISM Manufacturing PMI Tops Estimates

Senti Biosciences Inc

– Approximately $10 million additional investment in private placement equity financing –
– $1.5 million from CIRM grant first announced in June 2024 –
– Cash runway guidance extended into 2026 –
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has secured an additional investment of approximately $10.0 million in gross proceeds from Celadon Partners adding to the <a href="https://www.globenewswire.com/Tracker?data=iAkBm0zHOsT51EGtqFQ1kHb5qPG1rXl_7VF64BEFGvBwvNKwpaTqN4v4Zj9SglGWGP40M9WcSatDDQks_FhliK4yB_tYOoF_nUTi-U4635GRDqCcIF_PCLX3SvLxqpN7SeA-PkGud8CtmbD4Iul_dgYNffKjEcqcAnw8H3Bryfgl3R0fOWS24Kp0gs93EdToZqzyC46wGz5f4kBv9tHAwiBes2mlTu8UksClFiAe3DtUR7M8zDg9u5kZIcWHqFW6">previously announced PIPE financing round</a>.
This additional funding brings the total raised in the round to $47.6 million.

Financing

Senti Bio Announces Additional $11.5M Of Financing; ~$10M Additional Investment In Private Placement Equity Financing; $1.5M From CIRM Grant First Announced In June 2024; Cash Runway Guidance Extended Into 2026

Senti Biosciences's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NYSE">SNTI</a>) short percent of float has risen 76.07% since its last report. The company recently reported that it has 103 thousand shares sold short, which is 2.87% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Senti Biosciences Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1735737321_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Senti Biosciences has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Senti Biosciences's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Senti Biosciences's peer group average for short interest as a percentage of float is 3.83%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Senti Biosciences?

Biotech

Senti Bio Doses First Patient In Clinical Trial Of SN301A In Hepatocellular Carcinoma In Collaboration With Celest Therapeutics

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Stifel raised the price target for Couchbase, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) from $20 to $22. Stifel analyst Brad Reback maintained a Buy rating. Couchbase shares closed at $21.12 on Tuesday. <a href="https://www.benzinga.com/quote/BASE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley boosted the price target for Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) from $330 to $405. Morgan Stanley analyst Keith Weiss maintained an Overweight rating. Salesforce shares closed at $331.43 on Tuesday. <a href="https://www.benzinga.com/quote/CRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group boosted Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) price target from $122 to $127. Evercore ISI Group analyst Mark Lipacis maintained an Outperform rating. Marvell Technology shares settled at $95.91 on Tuesday. <a href="https://www.benzinga.com/quote/MRVL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird raised MongoDB, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) price target from $305 to $380. Baird analyst William Power maintained an Outperform rating. MongoDB shares closed at $324.01 on Tuesday. <a href="https://www.benzinga.com/quote/MDB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Northland Capital Markets increased The Honest Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNST#NASDAQ">HNST</a>) price target from $7.5 to $9.5. Northland Capital Markets analyst Owen Rickert maintained an Outperform rating. Honest Company shares closed at $8.01 on Tuesday.  <a href="https://www.benzinga.com/quote/HNST/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods boosted Willis Towers Watson Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTW#NASDAQ">WTW</a>) price target from $359 to $378. Keefe, Bruyette &amp; Woods analyst Meyer Shields maintained an Outperform rating on the stock. Willis Towers Watson shares closed at $329.06 on Tuesday. See how other analysts view this stock.</li>
<li>Chardan Capital increased the price target for Senti Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) from $10 to $12. Chardan Capital analyst Geulah Livshits maintained a Buy rating. Senti Biosciences shares settled at $7.14 on Tuesday. <a href="https://www.benzinga.com/quote/SNTI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays cut The J. M. Smucker Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJM#NYSE">SJM</a>) price target from $126 to $123. Barclays analyst Andrew Lazar maintained an Equal-Weight rating. Smucker shares closed at $117.29 on Tuesday. <a href="https://www.benzinga.com/quote/SJM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan increased the price target for Trimble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMB#NASDAQ">TRMB</a>) from $74 to $92. JP Morgan analyst Tami Zakaria upgraded the stock from Neutral to Overweight. Trimble shares closed at $73.95 on Tuesday. <a href="https://www.benzinga.com/quote/TRMB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays raised AT&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>) price target from $24 to $27. Barclays analyst Kannan Venkateshwar maintained an Overweight rating. AT&amp;T shares closed at $23.74 on Monday. <a href="https://www.benzinga.com/quote/T/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying T stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="558" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/04082646/image-36-1024x558.png" alt="" class="wp-image-676409" style="width:558px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/04082646/image-36-1024x558.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/04082646/image-36-300x163.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/04082646/image-36-768x419.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/04082646/image-36.png 1167w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42293707/jim-cramer-prefers-this-delivery-giant-over-ups">Jim Cramer Prefers FedEx Over This Delivery Giant That &#8216;Screwed Up A Lot Of Holiday Seasons&#8217;</a></li>
</ul>

AT&T To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday

Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) with a Buy and raises the price target from $10 to $12.

Chardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $12

Senti Biosciences Shares Resume Trade

Senti Biosciences Shares Halted On Circuit Breaker To The Downside, Stock Now Down -17.6%

U.S. stock futures were in negative territory during Tuesday&#8217;s premarket hours as the dollar slipped to 106.3 level.
The U.S. 10-year and two-year Treasury notes yielded 4.21% and 4.18%, respectively. Expectations of a further 25 basis point rate cut in December rose to 72.5%, according to <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">CME Group&#8217;s FedWatch tool</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.08%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.02%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.07%</td>
</tr>
<tr>
<td>Russel 2000</td>
<td>-0.11%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Monday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was down 0.01% to $603.60 and the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.09% to $514.84, according to <a href="https://www.benzinga.com/">Benzinga Pro</a> data.
Cues From The Last Session
The U.S. stock market closed higher on Monday, with the <a href="https://www.benzinga.com/24/12/42282669/sp-nasdaq-settle-at-record-highs-as-tesla-shares-surge-investor-sentiment-decreases-but-fear-greed-index-remains-in-greed-zone">S&amp;P 500 and Nasdaq Composite reaching new highs</a>.
Key Drivers:
<ul>
<li>Tesla Boost: Tesla shares surged 3.5% after Roth MKM upgraded the stock and raised its price target.</li>
<li>Super Micro Rebound: Super Micro Computer stock jumped 29% following a positive company announcement.</li>
<li>Economic Data: U.S. construction spending increased and the ISM manufacturing PMI rose, beating expectations.</li>
<li>Sector Performance: While most S&amp;P 500 sectors closed lower, communication services and consumer discretionary stocks outperformed. Utilities, real estate, and financials lagged.</li>
</ul>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.97%</td>
<td>19,404</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.24%</td>
<td>6,047.15</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.29%</td>
<td>44,782</td>
</tr>
<tr>
<td>Russel 2000</td>
<td>-0.02</td>
<td>2,434</td>
</tr>
</tbody>
</table>
</figure>
Also read: <a href="https://www.benzinga.com/markets/equities/24/12/42282948/ubs-forecasts-sp-500-to-hit-6600-in-2025-citing-support-from-over-easy-global-central-bank-policy">UBS Forecasts S&amp;P 500 To Hit 6,600 In 2025, Citing Support From &#8216;Over-Easy Global Central Bank Policy&#8217;</a>
Insights From Analysts: Chief investment officer at UBS Global Wealth Management, Mark Haefele termed the decade so far as the &#8220;Roaring 20s,&#8221; marked by high economic growth, strong market returns, and improving productivity.
In his ‘<a href="https://www.ubs.com/global/en/wealthmanagement/insights/chief-investment-office/roaring-20s-the-next-stage.html#review">UBS Year Ahead 2025 Report</a>‘ he said "After strong years for equities in 2023 and 2024, we see further upside in 2025. We expect the S&amp;P 500 to reach 6,600 by the end of 2025, around 10% higher than today&#8217;s levels."
"We expect central banks to cut interest rates further in the year ahead, reducing cash returns," Haefele added.
Highlighting his economic outlook he said, "In our base case, we expect sustained economic growth in the U.S., supported by healthy consumption, loose fiscal policy, and lower interest rates. Tariff threats are a headwind for Asia and Europe. If imposed, they could be partially offset by reactive stimulus measures in China."
Chief market strategist at Carson Group LLC, Ryan Detrick highlighted that &#8220;With a new high in December, we&#8217;ve seen new highs in 10 out of 12 months this year (April and August didn&#8217;t).&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Today was the 54th all-time high in &#39;24 for the S&amp;P 500. Officially the 5th most ever (since 1957 when it moved to 500 stocks). 62 in 2017 is next up. With a new high in December, we&#39;ve seen new highs in 10 out of 12 months this year (April and August didn&#39;t). Not bad. <a href="https://t.co/FiEJ27kjVr">pic.twitter.com/FiEJ27kjVr</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1863771861034668045?ref_src=twsrc%5Etfw">December 3, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Unrelated to past cycles, global central banks are easing monetary policy despite strong economic growth, high asset prices, and elevated inflation, said Bob Elliott, the chief investment officer at Unlimited Funds. Elliott presented the underlying data reiterating these conditions in a thread on X, indicating a positive sign for the markets.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The global economy is getting a shot of adrenaline from a coordinated central bank easing. But unlike the past, it comes at a time when growth is pretty good, asset prices are near highs, and inflation remains elevated. Thread.
&mdash; Bob Elliott (@BobEUnlimited) <a href="https://twitter.com/BobEUnlimited/status/1863551595545334237?ref_src=twsrc%5Etfw">December 2, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Upcoming Economic Data
This week&#8217;s economic calendar is packed after a short last week due to Thanksgiving.
<ul>
<li>On Tuesday, job openings data for October will be released at 10:00 a.m. ET and auto sales data will be released for which the time is yet to be determined.</li>
<li>On Wednesday, November&#8217;s data on ADP employment will be released at 8:15 a.m. ET.</li>
<li>St. Louis Fed President Musalem will speak at 8:45 a.m. ET.</li>
<li>The S&amp;P final U.S. services PMI for November will be released at 9:45 a.m. ET.</li>
<li>The ISM services and factory orders data for November and October, respectively, will be released at 10:00 a.m. ET.</li>
<li>Fed Beige Book will be released at 2:00 p.m. ET.</li>
<li>On Thursday, initial jobless claims data for November and U.S. trade deficit data for October will be released at 8:30 a.m. ET.</li>
<li>On Friday, the U.S. employment report, U.S. unemployment rate, and U.S. hourly wages data will be released at 8:30 a.m. ET.</li>
<li>The preliminary data for consumer sentiment will be released at 10 a.m. ET.</li>
<li>Chicago Fed President Goolsbee will speak at 10:30 a.m., ET.</li>
<li>Consumer credit data will be released at 3:00 p.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Shimmick Construction (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIM#NASDAQ">SHIM</a>) was 57.5% higher at $4.43 apiece in premarket after it landed a $45.4 million contract to build the Murray Street Bridge in Santa Cruz.</li>
<li>Super Micro Computer Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)<a href="https://www.benzinga.com/24/12/42284776/super-micro-shares-rise-over-7-in-premarket-after-independent-special-committee-found-no-evidence-of-misconduct-but-top-investment-bank-flags-two-key-points-to-watch"> was 6.67% up</a> at $44.8 per share after it announced that the independent Special Committee formed by the company&#8217;s board completed its review.</li>
<li>Santi Biosciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares were 4.50% down at $9.55 apiece after it secured a $37.6 million private placement financing through the sale of 16,713 shares of Series A Convertible Preferred Stock.</li>
<li>Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares were down 1.3% to $352.44 apiece after Elon Musk&#8217;s pay package was rejected again by a Delaware judge despite being approved by Tesla shareholders at a June meeting.</li>
<li>Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) was up 0.17% at $23.97 per share after the retirement announcement of its chief executive officer, Pat Gelsinger.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures rose in the early New York session, advancing 0.91% to hover around $68.72.
The Dollar Index was down 0.12% to 106.3 level. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) was down 0.16% over the past 24 hours and traded just over the $95K mark.
Major Asian markets closed higher on Tuesday. European markets were also upbeat. 
<ul>
<li>Read next: <a href="https://www.benzinga.com/24/12/42283257/charles-schwab-goldman-sachs-invesco-add-mara-holdings-morgan-stanley-cuts-stake-here-is-what-changed-with-mara-holdings-in-q3">Charles Schwab, Goldman Sachs Boosts MARA Stake As Stock Rallies 30% In Past 6 Months: Morgan Stanley, Other Major Funds Trim Positions In Q3</a></li>
</ul>
Image via Shutterstock

US Stock Futures Dip As Dollar Slides And Treasuries Rise After S&P Hits 54th All-Time High This Year: Analyst Sees 'Further Upside' Of Around 10% In 2025 From Current Levels

<h3>Gainers</h3>
<ul>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) stock moved upwards by 227.8% to $7.08 during Monday's pre-market session. The market value of their outstanding shares is at $32.4 million. </li>
<li>Purple Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBT#NASDAQ">PPBT</a>) stock moved upwards by 50.22% to $5.04. The market value of their outstanding shares is at $170.9 million. </li>
<li>NovoCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) stock rose 40.26% to $28.11. The market value of their outstanding shares is at $3.0 billion. </li>
<li>Cabaletta Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) shares moved upwards by 36.12% to $5.2. The market value of their outstanding shares is at $254.1 million. </li>
<li>Scienture Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) stock moved upwards by 22.44% to $9.0. The company's market cap stands at $71.3 million. </li>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) shares moved upwards by 19.25% to $12.88. The market value of their outstanding shares is at $106.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>BrightSpring Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTSGU#NASDAQ">BTSGU</a>) stock declined by 16.9% to $59.1 during Monday's pre-market session. </li>
<li>Avenue Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) stock decreased by 16.57% to $1.79. The company's market cap stands at $3.4 million. </li>
<li>RenovoRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNXT#NASDAQ">RNXT</a>) stock fell 9.45% to $1.15. The company's market cap stands at $27.6 million. </li>
<li>Repare Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) stock decreased by 8.24% to $3.01. The company's market cap stands at $127.9 million. </li>
<li>Biomerica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) shares declined by 7.84% to $0.36. The company's market cap stands at $6.0 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares decreased by 7.53% to $2.7. The company's market cap stands at $31.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ATXI

BMRA

BTSGU

CABA

CRVO

PPBT

RNXT

RPTX

SCNX

12 Health Care Stocks Moving In Monday's Pre-Market Session

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 150 points on Monday.
The Dow traded down 0.34% to 44,759.96 while the NASDAQ gained 1.03% to 19,416.22. The S&amp;P 500 also rose, gaining, 0.26% to 6,047.97.
Check This Out: <a href="https://www.benzinga.com/top-stories/24/12/42265024/how-to-earn-500-a-month-from-marvell-technology-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Marvell Technology Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Communication services shares jumped by 1% on Tuesday.
In trading on Tuesday, utilities shares fell by 1.9%.
Top Headline
The ISM manufacturing PMI rose to 48.4 in November versus 46.5 in the previous month, beating market estimates of 47.7.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Senti Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares shot up 540% to $13.79 after the company announced a private investment in public equity to issue and sell an aggregate of 16,713 shares of Series A Convertible Preferred Stock.</li>
<li>Shares of NovoCure Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) got a boost, surging 30% to $26.05 after the company announced its Phase 3 PANOVA-Trial met its primary endpoint and demonstrated a statistically significant improvement in its median overall survival rate.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares were also up, gaining 20% to $39.25 after the company announced it completed a review by an independent special committee and stated EY&#8217;s conclusions were not supported by findings.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Mondee Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOND#NASDAQ">MOND</a>) shares dropped 41% to $0.4159 after the company announced it received a delist determination notice from the Nasdaq.</li>
<li>Shares of Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) were down 14% to $67.94 after JP Morgan downgraded the stock from Neutral to Underweight.</li>
<li>Revolution Medicines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVMD#NASDAQ">RVMD</a>) was down, falling 13% to $50.34. The company provided key clinical updates from its RAS(ON) inhibitor portfolio.</li>
</ul>
Commodities In commodity news, oil traded up 0.4% to $68.30 while gold traded down 0.6% at $2,665.60.
Silver traded down 0.9% to $30.835 on Monday, while copper fell 0.4% to $4.1220.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 gained 0.38%, Germany's DAX climbed 1.15% and France's CAC 40 fell 0.43%. Spain's IBEX 35 Index rose 0.40%, while London's FTSE 100 rose 0.07%.
Asia Pacific Markets
Asian markets closed higher on Monday, with Japan's Nikkei 225 gaining 0.80%, Hong Kong's Hang Seng Index gaining 0.65%, China's Shanghai Composite Index climbing 1.13% and India's BSE Sensex gaining 0.56%.
Economics
<ul>
<li>U.S. construction spending increased by 0.4% month-over-month to an annual rate of $2,174 billion in October compared to a 0.1% gain in September.</li>
<li>The ISM manufacturing PMI rose to 48.4 in November versus 46.5 in the previous month, beating market estimates of 47.5.</li>
<li>The S&amp;P Global US manufacturing PMI rose to 49.7 in November compared to a preliminary reading of 48.8, and versus 48.5 in October.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42264122/wall-streets-most-accurate-analysts-give-their-take-on-3-financial-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Financial Stocks Delivering High-Dividend Yields</a></li>
</ul>

Senti Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) stock is skyrocketing on Monday, with a strong session volume of 73.4 million compared to an average volume of 17.81 thousand, as per data from <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.
The company reported initial clinical data from a Phase 1 trial of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy, for relapsed/refractory hematologic malignancies including <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42263057/senti-bio-announces-positive-initial-clinical-data-in-phase-1-clinical-trial-of-senti-202-a-logic-" rel="noreferrer noopener">acute myeloid leukemia</a>.
SENTI-202 is designed to selectively target and eliminate CD33 and/or FLT3-expressing hematologic malignancies while sparing healthy bone marrow cells.
Three AML patients have been treated at the lowest dose level (1.0 billion CAR+ NK cells per dose) and, as of the data cutoff date of September 19, two achieved complete remission, confirmed by bone marrow biopsy, which includes blast reduction and recovery of blood cells to normal ranges.
In addition, both patients were assessed as measurable residual disease negative after treatment, defined as no detectable cancer cells in a bone marrow sample.
Both patients maintain remission (4+ months and 3+ months, respectively).
The Safety Review Committee cleared the lowest dose cohort, and dose escalation continues at the 1.5 billion CAR+ NK cells/dose level.
SENTI-202 was generally well-tolerated with no dose-limiting toxicities and an adverse event profile consistent with other investigational NK cell therapies and patients with underlying AML receiving lymphodepleting chemotherapy.
SENTI-202 transgene was detected in the peripheral circulation of all three patients and all cycles, with a pharmacokinetic profile generally consistent with other investigational CAR-NK therapy levels.
The company expects to enroll approximately 20 patients in the Phase 1 trial. A higher dose cohort of 1.5 billion CAR+ NK cells/dose is actively enrolling.
Additional safety and efficacy data, including initial durability data, are expected in 2025.
Concurrently, Senti Biosciences announced a private investment in public equity financing to issue and sell an aggregate of 16,713 shares of Series A Convertible Preferred Stock, with gross proceeds of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42263313/senti-biosciences-inc-announces-oversubscribed-37-6-million-private-placement-equity-financing" rel="noreferrer noopener">approximately $37.6 million</a>.
The company has also granted a certain investor an option to purchase an additional 4,444 shares of Preferred Stock and accompanying warrants for gross proceeds of approximately $10.0 million.
Senti Biosciences also announced that it has appointed Fran Schulz, an experienced biotechnology and financial executive, to the Senti Bio Board of Directors. Omid Farokhzad is departing from the <a target="_blank" href="https://www.benzinga.com//node/42262836" rel="noreferrer noopener">Board in conjunction with Schulz&#8217;s appointment.</a>
Price Action: SNTI stock is up 439% at $11.66 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42268730/novocures-recently-approved-tumor-treating-electric-fields-shows-promise-in-pancreatic-cancer-patients" target="_blank" rel="noreferrer noopener">NovoCure&#8217;s Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients</a></li>
</ul>
Illustration of Phrama lab worker created with MidJourney.

Health Care

Why Is Senti Biosciences Stock Surging Over 400% On Monday?

Senti Biosciences Shares Halted On Circuit Breaker To The Upside, Stock Now Up 492.6%

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points on Monday.
Following the market opening Monday, the Dow traded up 0.09% to 44,953.54 while the NASDAQ gained 0.54% to 19,322.17. The S&amp;P 500 also rose, gaining, 0.21% to 6,045.08.
Check This Out: <a href="https://www.benzinga.com/top-stories/24/12/42265024/how-to-earn-500-a-month-from-marvell-technology-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Marvell Technology Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Consumer discretionary shares jumped by 1.3% on Monday.
In trading on Monday, real estate shares fell by 0.6%.
Top Headline
Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) said on Sunday that it delivered 48,740 vehicles in November, marking an 18.8% jump in sales year-over-year but a 5.3% drop from October when it delivered 51,443 vehicles.
The rise in sales, Li Auto said, could be attributed to robust sales across its model lineup.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Senti Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares shot up 244% to $7.42 after the company announced a private investment in public equity to issue and sell an aggregate of 16,713 shares of Series A Convertible Preferred Stock.</li>
<li>Shares of Safe &amp; Green Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) got a boost, surging 69% to $0.8267.</li>
<li>ParaZero Technologies Ltd.. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRZO#NASDAQ">PRZO</a>) shares were also up, gaining 60% to $1.9799. ParaZero Technologies recently announced it received a designation verification report approval from the European Union Aviation Safety Agency for its SafeAir M-300 Pro and SafeAir M-350 Pro parachute safety kits.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Mondee Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOND#NASDAQ">MOND</a>) shares dropped 20% to $0.5711 after the company announced it received a delist determination notice from the Nasdaq.</li>
<li>Shares of Thunder Power Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIEV#NASDAQ">AIEV</a>) were down 20% to $0.3741.</li>
<li>Trident Digital Tech Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDTH#NASDAQ">TDTH</a>) was down, falling 15% to $2.25.</li>
</ul>
Commodities In commodity news, oil traded up 1.3% to $68.89 while gold traded down 0.4% at $2,669.70.
Silver traded down 0.4% to $30.990 on Monday, while copper fell 0.1% to $4.1350.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.6%, Germany's DAX climbed 1.3% and France's CAC 40 gained 0.1%. Spain's IBEX 35 Index rose 0.7%, while London's FTSE 100 rose 0.4%.
Asia Pacific Markets
Asian markets closed mostly higher on Monday, with Japan's Nikkei 225 gaining 0.80%, Hong Kong's Hang Seng Index gaining 0.65%, China's Shanghai Composite Index climbing 1.13% and India's BSE Sensex gaining 0.56%.
Economics
The manufacturing PMI will be released today.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42264122/wall-streets-most-accurate-analysts-give-their-take-on-3-financial-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Financial Stocks Delivering High-Dividend Yields</a></li>
</ul>

AIEV

PRZO

SGBX

TDTH

Nasdaq Gains Over 100 Points; Li Auto Delivers 48,740 Vehicles In November

WIIM

Senti Biosciences shares are trading higher after the company announced a private investment in public equity to issue and sell an aggregate of 16,713 shares of Series A Convertible Preferred Stock.

Offerings

Senti Biosciences Announced A Private Investment In Public Equity To Issue And Sell An Aggregate Of 16,713 Shares Of Series A Convertible Preferred Stock, With Gross Proceeds Of Approximately $37.6M

<ul>
<li>2 of 3 patients achieved MRD negative CR in the first dose level evaluated in the trial with a generally well-tolerated preliminary safety profile.</li>
<li>Dose escalation is continuing with additional response and durability data expected in 2025.</li>
</ul>

Senti Biosciences Reported Initial Clinical Data From A Phase 1 Trial Of SENTI-202 For Relapsed/Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

Senti Biosciences Q3 EPS $(6.31) Down From $(3.36) YoY; Revenue $0M Down From $0.338M YoY

<h3>Gainers</h3>
<ul>
<li>Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) shares increased by 28.2% to $5.16 during Wednesday's regular session. The company's market cap stands at $2.9 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares rose 26.07% to $2.74. The market value of their outstanding shares is at $4.9 million. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) stock moved upwards by 20.59% to $0.11. The company's market cap stands at $5.8 million. </li>
<li>Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) stock increased by 19.78% to $10.9. The market value of their outstanding shares is at $385.1 million. </li>
<li>Corbus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) stock increased by 14.51% to $21.0. The company's market cap stands at $252.9 million. </li>
<li>Eterna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) shares increased by 12.7% to $1.27. The market value of their outstanding shares is at $6.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares declined by 15.6% to $0.14 during Wednesday's regular session. The market value of their outstanding shares is at $4.1 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) stock fell 12.97% to $2.55. The market value of their outstanding shares is at $11.6 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares declined by 11.66% to $2.88. The company's market cap stands at $4.6 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) shares fell 10.74% to $0.48. The market value of their outstanding shares is at $1.3 million. </li>
<li>Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) shares decreased by 10.65% to $19.84. The market value of their outstanding shares is at $1.7 billion. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) shares declined by 10.64% to $0.41. The market value of their outstanding shares is at $3.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BBLG

CAPR

CERO

CRBP

ERNA

FTRE

OGEN

STSS

TNON

VTAK

WINT

12 Health Care Stocks Moving In Wednesday's Intraday Session

Senti Biosciences shares are trading higher after the company announced a year-over-year increase in Q2 EPS results.

Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) reported quarterly losses of $(2.45) per share. This is a 41.67 percent increase over losses of $(4.22) per share from the same period last year.

Senti Biosciences Q2 EPS $(2.45) Up From $(4.22) YoY

The company states: "Senti Bio (SNTI)science reported positive initial clinical data from a Phase 1 clinical trial of SENTI-202, a potential first-...

Senti Bio reports positive initial clinical data from Phase 1 trial of SENTI-202

Senti Biosciences ( ($SNTI) ) has issued an announcement. Senti Biosciences reported encouraging initial results from a Phase 1 clinical trial of S...

Senti Biosciences' SENTI-202 Shows Promising Phase 1 Results

Analyst Geulah Livshits of Chardan Capital reiterated a Buy rating on Senti Biosciences (SNTI – Research Report), with a price target of $10.00. Ge...

Buy Rating on SENTI-202 Driven by Promising Trial Results and Financial Support

Senti Biosciences ( ($SNTI) ) has shared an announcement. Senti Biosciences, a biotech company, entered a $47.6 million securities purchase agreeme...

Senti Biosciences Advances with Key Financial and Strategic Moves

09:33 EST Senti Bio (SNTI)sciences Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, mark...

Senti Biosciences Inc trading halted, volatility trading pause

09:38 EST Senti Bio (SNTI)sciences Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financ...

Senti Biosciences Inc trading resumes

Chardan analyst Geulah Livshits raised the firm's price target on Senti Bio (SNTI) to $12 from $10 and keeps a Buy rating on the shares after the c...

Senti Bio price target raised to $12 from $10 at Chardan

Senti Bio (SNTI)sciences announced that the first patient has been dosed in the pilot trial of SN301A in HCC in mainland China in collaboration wit...

Senti Bio announces first patient dosed in clinical trial of SN301A

Senti Biosciences receives additional investment of $10M

Senti Bio (SNTI)sciences has secured an additional investment of approximately $10.0 million in gross proceeds from Celadon Partners adding to the ...

Senti Bio announces additional $11.5M in financing

Press Releases

Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202

Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights

Senti Bio to Participate in Upcoming Investor Conferences

Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights

Management

Senti Bio Appoints Fran Schulz to Board of Directors

Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML

Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing

Senti Biosciences Announces New Employment Inducement Grants

Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics

Senti Bio Announces Additional $11.5 Million of Financing

EDAP

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

Aprea Therapeutics

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

CervoMed

Equillium

Eterna Therapeutics

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

Geovax Labs

HOOKIPA Pharma

IN8bio

Kairos Pharma

Longeveron

MEI Pharma

Nanoviricides

NextCure

Ocean Biomedical

Pluri

Palatin Techs

Synlogic

Tenax Therapeutics

Chardan Capital

Morgan Stanley

B of A Securities

Comments

Senti Biosciences

Senti Biosciences (SNTI) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga